Aquestive Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Aquestive Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Locked Ratio: Money owed to suppliers is larger than money owed by customers plus stock: $14 per $100 of sales comes from others' credit, against $0 tied up three years earlier. Less money tied up than 95% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-55.1×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 74% of Healthcare companies in United States.
Cash Locked Ratio
−$14Money owed to suppliers is larger than money owed by customers plus stock: $14 per $100 of sales comes from others' credit, against $0 tied up three years earlier.
Less money tied up than 95% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
2/3 · 1/3Sales grew in 2 of the last 3 years; profit grew in 1 of 3.
Less steady than 51% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 7%
Sales fell 7% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-7% / +181%In 3 years sales changed by -7% while total assets changed by +181%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-5.2×Operating cash was negative last year, while some debt falls due within a year.
Higher than 59% of Healthcare companies in United States.
Cash Cushion Ratio
+16%Cash, after subtracting all debt, equals 16% of its market value (net cash).
Higher than 58% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
Aquestive Therapeutics, Inc. made a loss over the last year. Aquestive Therapeutics, Inc. owes $1.43 for every $1 it owns. Aquestive Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossAquestive Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
-8.87Aquestive Therapeutics, Inc.'s book value is negative (it owes more than it owns), so P/B is not meaningful.
Market cap
$502 MThe total market value of all of Aquestive Therapeutics, Inc.'s shares at today's price (share price × number of shares), larger than 55% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
NegativeAquestive Therapeutics, Inc.'s net worth is negative ($57 M below zero, balance sheet 30 Jun 2026): it owes more than it owns, so book value per share and P/B are not meaningful.
Owes vs Owns
1.43×Aquestive Therapeutics, Inc. owes $1.43 for every $1 it owns, so it owes more than it owns, higher than 94% of Healthcare companies in United States.
Dividend yield
NoneAquestive Therapeutics, Inc. does not currently pay a dividend.
Revenue growth
-23%Revenue fell 23% in the year to Dec 2025, and shrank 2% a year on average over 3 years.
Profit growth
LossAquestive Therapeutics, Inc. made a loss in each of the last two years.
Profit margin
-188.1%Aquestive Therapeutics, Inc. lost $188 for every $100 of revenue.
Interest cover
Not coveredAquestive Therapeutics, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashAquestive Therapeutics, Inc. held $79 M more cash than debt (net cash) at Dec 2025.
Questions
How much does Aquestive Therapeutics, Inc. owe compared with what it owns?
Aquestive Therapeutics, Inc. owes $1.43 for every $1 it owns, so it owes more than it owns, higher than 94% of Healthcare companies in United States.
Does Aquestive Therapeutics, Inc. pay a dividend?
No. Aquestive Therapeutics, Inc. does not currently pay a dividend.
Is Aquestive Therapeutics, Inc.'s revenue growing?
Revenue fell 23% in the year to Dec 2025, and shrank 2% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.